ARS Pharmaceuticals (SPRY) insider plans sale after Aug. 18–19 stock disposals
Sarina Tanimoto, an insider at ARS Pharmaceuticals (SPRY), has filed a Form 144 indicating an intended sale of 25,000 shares of common stock, valued at $147,970.00, on August 20, 2026. This planned sale is connected to a stock option exercise for cash. The filing also reports that Tanimoto previously sold 25,000 shares on August 19, 2026, and 49,401 shares on August 18, 2026.
ARS Pharmaceuticals (NASDAQ: SPRY) holder plans 25K-share sale after 100K sold
Richard Lowenthal, a holder of ARS Pharmaceuticals (NASDAQ: SPRY) common stock, intends to sell 25,000 shares on August 20, 2026, through Morgan Stanley Smith Barney LLC after exercising a stock option, with an aggregate market value of $148,160.00. This planned sale follows two previous sales by Lowenthal within the last three months, totaling 100,000 shares sold on August 18 and 19, 2026, for over $638,000. The transaction was disclosed in an SEC Form 144 filing, outlining details about the sale and Lowenthal's relationship to the issuer as an officer, director, and 10% stockholder.
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact SueWallSt
A securities class action has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) by SueWallSt on behalf of shareholders who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the approval timeline for neffy on CVS Caremark's formulary, specifically concerning a targeted July 1, 2026, effective date which was not met. When the company announced no new coverage decisions for neffy in the July 1, 2026 cycle, SPRY shares dropped by approximately 23.9% ($2.52 per share), leading to significant investor losses.
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 6.3% - What's Next?
ARS Pharmaceuticals (NASDAQ:SPRY) shares dropped 6.3% to $5.98 on unusually light trading volume. Despite missing quarterly EPS estimates with a loss of $0.63 per share, the company's revenue of $33.66 million exceeded forecasts, and analysts maintain a "Moderate Buy" rating with an average price target of $28.20. Insider selling by Eric Karas and Alexander A. Fitzpatrick was also noted.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and its officers. The lawsuit alleges that ARS Pharmaceuticals made materially false and misleading statements to investors regarding the expected timeline for expanded insurance coverage of its product, neffy, through CVS Caremark. Investors who purchased ARS securities between March 9, 2026, and June 24, 2026, are encouraged to join the case, with a lead plaintiff deadline of October 5, 2026.
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit was prompted by a significant stock drop after ARS Pharmaceuticals announced that no new commercial formulary additions or coverage decisions had been issued for its drug neffy in the July 1, 2026 cycle. Investors have until October 5, 2026, to move to serve as lead plaintiff.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
The Rosen Law Firm is encouraging investors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to secure counsel before the October 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expected timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, through CVS Caremark, causing investors to purchase securities at inflated prices. Investors who purchased ARS Pharmaceuticals securities between March 9, 2026, and June 24, 2026, may be entitled to compensation.
ARS Pharmaceuticals (NASDAQ: SPRY) holder lines up new 50K-share sale
Richard Lowenthal, a holder of ARS Pharmaceuticals (NASDAQ: SPRY) stock, has filed a Rule 144 notice to sell up to 50,000 common shares. This proposed sale, valued at approximately $322,345, is related to a stock option exercise and follows a previous sale of 50,000 shares on August 18, 2026. The transaction will be executed for cash through Morgan Stanley Smith Barney LLC on NASDAQ.
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) and its officers. The lawsuit, filed on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026, alleges that the company made materially false and misleading statements regarding the timeline for expanded insurance coverage for neffy. Investors with substantial losses have until October 5, 2026, to request to be appointed as lead plaintiff in the case.
SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has announced a shareholder alert for investors in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) who suffered losses. The class action lawsuit alleges the company made misleading statements regarding expanded CVS Caremark coverage for its product neffy, leading to a significant stock price decline. Investors who purchased securities between March 9, 2026, and June 24, 2026, are encouraged to contact the firm by October 5, 2026, to be considered for lead plaintiff.
ARS Pharmaceuticals (NASDAQ: SPRY) stockholder plans 49K-share sale
A stockholder of ARS Pharmaceuticals (NASDAQ: SPRY), Sarina Tanimoto, has filed a Rule 144 notice indicating a planned sale of up to 49,401 shares of common stock. These shares originate from a stock option exercise for cash and are expected to be sold on or after August 18, 2026, through Morgan Stanley Smith Barney LLC, with an aggregate market value of $311,191.72. The filing provides key details about the proposed transaction and the regulatory context of Rule 144.
SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), announcing a securities class action lawsuit. This alert is for investors who purchased SPRY shares between March 9, 2026, and June 24, 2026, due to alleged misleading statements regarding expanded insurance coverage for neffy. The lawsuit claims that ARS Pharmaceuticals failed to disclose that expanded insurance coverage for neffy through CVS Caremark would not be secured by the guided July 1, 2026 deadline, leading to a significant stock price drop.
Lead Plaintiff Deadlines in Shareholder Class Action
Holzer & Holzer, LLC is reminding investors of upcoming lead plaintiff deadlines in class action lawsuits against ARS Pharmaceuticals, Inc. (SPRY), Alarum Technologies Ltd. (ALAR), and HDFC Bank Limited (HDB). Investors who purchased shares in these companies during specified periods and suffered losses are encouraged to contact the firm to discuss their legal rights. The deadlines to seek appointment as lead plaintiff are October 5, 2026, for ARS Pharmaceuticals and Alarum Technologies, and October 12, 2026, for HDFC Bank.
ARS Pharmaceuticals (NASDAQ: SPRY) CCO files first insider report with no shares
ARS Pharmaceuticals' Chief Commercial Officer, Margaret Ekins Smith, has filed her initial insider ownership report (Form 3) with the SEC. The filing indicates that she currently holds no shares and has reported no buy or sell transactions. This report merely establishes her status as an insider with the company.
Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit
Robbins LLP is urging stockholders of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) who incurred losses to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements about the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. The stock price declined significantly after it was revealed that the expected coverage by July 1, 2026, did not materialize, leading to a drop of over 23.9% in one day.
Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit
Robbins LLP is urging stockholders of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) who incurred losses between March 9, 2026, and June 24, 2026, to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements about the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, through CVS Caremark, particularly for the summer and back-to-school allergy seasons. The company's stock price dropped significantly after it was announced that the expanded coverage would not be in place by the July 1, 2026 deadline as previously suggested.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and its officers, alleging violations of federal securities laws. The lawsuit claims that ARS Pharmaceuticals made misleading statements and concealed adverse facts regarding the expected timeline for expanded insurance coverage for neffy through CVS Caremark during the period of March 9, 2026, to June 24, 2026. Investors who purchased ARS securities during this period are encouraged to join the case, with a lead plaintiff deadline of October 5, 2026.
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a securities class action against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals failed to adequately warn investors that CVS Caremark's decision on neffy formulary coverage, initially targeted for July 1, 2026, could be delayed until January 2027, leading to a significant stock price drop. The firm is encouraging affected shareholders to contact them to learn more about recovering losses, with a lead plaintiff deadline of October 5, 2026.
Analysts Have Lowered Expectations For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Its Latest Results
Analysts have lowered their expectations for ARS Pharmaceuticals (NASDAQ: SPRY) after its second-quarter results, with shares falling 8.3%. While revenues beat expectations, statutory losses increased, leading to revised forecasts for 2026 revenues and an increase in loss per share estimates. Consequently, the consensus price target for the company has been reduced by 13% to US$23.25.
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ:SPRY) on behalf of investors who purchased shares between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements and concealed material adverse facts regarding the expected timeline for expanded insurance coverage for neffy through CVS Caremark. Investors who suffered losses have until October 5, 2026, to request to be appointed lead plaintiff.
Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which led to significant stock declines for these companies. Long-term shareholders are encouraged to contact the law office to explore options for corporate reforms and recovery of funds.
ARS Pharmaceuticals Q2 Earnings Call Highlights
ARS Pharmaceuticals (SPRY) outlined a revised commercial and spending strategy during its Q2 2026 earnings call, focusing on provider-targeted promotion for its neffy product and aiming for cash-flow breakeven by late 2027. The company reported $26.2 million in U.S. net product revenue for neffy, with its market share reaching 5% nationally and 8% in its field-sales targeted universe. ARS is shifting away from broad consumer advertising to more targeted provider engagement and expects to continue reducing operating expenses, while also advancing its neffy platform for chronic spontaneous urticaria (CSU) with a trial readout expected in early 2027.
ARS Pharmaceuticals (NASDAQ:SPRY) Posts Earnings Results, Misses Expectations By $0.15 EPS
ARS Pharmaceuticals (NASDAQ:SPRY) announced its quarterly earnings, reporting a Q2 EPS loss of $0.63, missing analyst estimates by $0.15, although revenue of $33.66 million surpassed expectations. Despite improved Neffy sales and a strategic shift towards targeted provider outreach, the company faces key risks including a delayed Phase IIb CSU trial readout, lower gross margins, and lawsuits related to CVS Caremark formulary coverage. Several analysts have updated their ratings on SPRY, and insider activity shows recent stock sales.
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS stock fell significantly after the company announced no new commercial formulary additions or coverage decisions for its drug neffy. Investors are encouraged to contact Kaplan Fox before the October 5, 2026, deadline to potentially serve as a lead plaintiff.
Earnings call transcript: ARS Pharmaceuticals shares fall after Q2 2026 report
ARS Pharmaceuticals reported Q2 2026 revenue of $33.7 million, exceeding analyst forecasts, but its shares fell significantly after hours due to concerns over high operating expenses and a delayed pipeline milestone. The company's intranasal epinephrine product, neffy, saw increased market share, and ARS Pharmaceuticals announced plans to cut SG&A and R&D spending by over 40% in the second half of 2026 to achieve cash flow breakeven by the end of 2027.
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
ARS Pharmaceuticals reported Q2 2026 financial results, including $26.2 million in U.S. neffy net product revenue. The company is shifting its commercial strategy to targeted provider engagement to reduce operating expenses and aims for cash flow breakeven by the end of 2027. ARS Pharma also announced the appointment of Meg Smith as Chief Commercial Officer and expects interim data from its Phase 2b trial in chronic spontaneous urticaria (CSU) in Q1 2027.
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) reported a Q2 loss of $0.63 per share, missing the Zacks Consensus Estimate of a $0.55 loss. However, the company surpassed revenue estimates, posting $33.66 million against an expectation of 5.54% less. Despite underperforming the market year-to-date, the stock holds a Zacks Rank #3 (Hold) based on mixed earnings estimate revisions.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
The Rosen Law Firm announces a class action lawsuit for purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026. Investors are encouraged to secure counsel by the October 5, 2026, deadline to serve as lead plaintiff. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expected timeline for insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark, leading to artificially inflated stock prices.
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
The Rosen Law Firm announces a class action lawsuit on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026. Investors who bought shares during this period are encouraged to secure counsel before the October 5, 2026 deadline to serve as lead plaintiff. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark, causing shareholders to suffer damages when the truth was revealed.
Did You Lose Money Investing in ARS Pharmaceuticals Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against SPRY
Robbins LLP is urging investors who suffered losses in ARS Pharmaceuticals Inc. (NASDAQ: SPRY) between March 9, 2026, and June 24, 2026, to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements about the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. The company's stock reportedly declined over 23.9% after announcing that the expected coverage would not be in place by July 1, 2026, as previously indicated.
Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY
Hennion & Walsh Asset Management Inc. has acquired 175,614 shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) valued at approximately $1.4 million, representing a 0.18% stake in the company. Institutional investors now collectively own 68.16% of ARS Pharmaceuticals. The company faces mixed analyst ratings, a consensus "Moderate Buy" with a target price of $28.20, and legal challenges regarding potential delays in insurance coverage for its neffy allergy treatment.
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm
Levi & Korsinsky, LLP has alerted stockholders of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a pending securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals failed to disclose the risk that CVS Caremark's formulary system could delay neffy coverage until January 2027, missing key allergy seasons. Investors who purchased shares between March 9, 2026, and June 24, 2026, and suffered losses may be eligible to join the class action, with October 5, 2026, set as the deadline to apply for lead plaintiff.
Lead Plaintiff Deadlines in Shareholder Class Action
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against ARS Pharmaceuticals, Inc. (SPRY), Alarum Technologies Ltd. (ALAR), and Blaize Holdings, Inc. (BZAI). The lawsuits allege false and misleading statements by the companies, with deadlines for lead plaintiff appointment set for October 5, 2026. Investors who suffered losses are encouraged to contact the firm.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $28.20. Despite this, the company faces a securities class-action lawsuit for investor purchases between March and June 2026, with a lead-plaintiff deadline of October 5, 2026. The company remains unprofitable, reporting a quarterly EPS of negative $0.61, and insider shares were recently sold under pre-arranged trading plans.
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit stems from a 23.9% drop in ARS stock price after the company announced no new commercial formulary additions or coverage decisions for its product neffy in the July 1, 2026 cycle. Investors with losses are encouraged to contact Kaplan Fox to learn about their legal rights and the lead plaintiff process, with a deadline to move the court by October 5, 2026.
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
The Rosen Law Firm announces a class action lawsuit against ARS Pharmaceuticals, Inc. on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expanded insurance coverage timeline for its epinephrine nasal spray, neffy, with CVS Caremark, causing shareholders to purchase stock at inflated prices. Investors with losses exceeding $100K are encouraged to seek lead plaintiff status by October 5, 2026.
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for investors who purchased securities between March 9, 2026, and June 24, 2026. This legal action follows a significant drop in ARS stock price after the company announced no new commercial formulary additions or coverage decisions for its product, neffy, in the July 1, 2026 cycle. Investors who suffered losses are encouraged to contact Kaplan Fox to learn about their legal rights and the lead plaintiff process, with a deadline to move the court by October 5, 2026.
ARS Pharmaceuticals Investors Face October Lawsuit Deadline
ARS Pharmaceuticals (NASDAQ: SPRY) is facing a securities class action lawsuit, with investors having until October 5, 2026, to seek lead plaintiff status. The lawsuit alleges the company misled investors about the expected timeline for expanded insurance coverage for its allergy treatment, neffy, specifically concerning delays with CVS Caremark. Following the disclosure of these delays in June 2026, ARS shares reportedly fell by approximately 23.9%.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. and its officers on behalf of investors who purchased ARS securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that the company made misleading statements and failed to disclose adverse facts regarding the expected timeline for expanded insurance coverage for neffy through CVS Caremark. Investors who suffered losses are encouraged to join the case by October 5, 2026, with the firm operating on a contingency fee basis.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) for alleged securities fraud, covering the period from March 9, 2026, to June 24, 2026. The lawsuit claims that ARS made false and misleading statements regarding the timeline for CVS Caremark's addition of neffy to its formulary, impacting the drug's commercialization. Investors who suffered losses during this period are encouraged to contact SBS Law to potentially lead the lawsuit before the October 5, 2026 deadline.
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline
The Gross Law Firm has issued a notice to investors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) regarding an upcoming securities class action deadline. The lawsuit alleges that the company made misleading statements concerning the expected timeline for expanded insurance coverage of its drug neffy through CVS Caremark, leading to a significant stock price decline when the coverage was not secured by the anticipated date. Shareholders who purchased SPRY shares between March 9, 2026, and June 24, 2026, are encouraged to register for the class action by October 5, 2026.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for alleged securities fraud. The lawsuit claims ARS Pharmaceuticals made false and misleading statements regarding the timeline for CVS Caremark's addition of neffy to its formulary. Investors who purchased SPRY shares between March 9, 2026, and June 24, 2026, have until October 5, 2026, to seek lead plaintiff appointment.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026, and June 24, 2026. The lawsuit alleges that the company made misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. Investors who wish to serve as lead plaintiff must move the Court no later than October 5, 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) after the Company disclosed that its flagship product, Neffy®, received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle, contrary to earlier optimistic statements. This news led to a sharp drop in ARS shares. The firm encourages investors to visit its site for more information and to assist with the investigation.
First Trust Advisors LP Purchases New Shares in ARS Pharmaceuticals, Inc. $SPRY
First Trust Advisors LP acquired 422,038 shares of ARS Pharmaceuticals (NASDAQ:SPRY) during the first quarter, valued at approximately $3.4 million, making them a new institutional investor in the company. Despite missing earnings estimates, the biopharmaceutical firm exceeded revenue expectations and maintains a "Moderate Buy" consensus from analysts with an average price target significantly above its current trading price. However, the company faces risks including insider share sales and investor lawsuits regarding alleged delays in CVS Caremark coverage for its product, neffy.
SPRY Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ARS Pharmaceuticals Inc.
Robbins LLP has filed a securities class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals failed to disclose that expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark might not be available by July 1, 2026, impacting sales during critical allergy seasons. This lack of disclosure led to a significant stock price decline when the information was revealed on June 24, 2026.
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and its officers, alleging that they made materially false and misleading statements regarding the expected timeline for expanded insurance coverage for neffy through CVS Caremark. The lawsuit seeks to recover damages for investors who purchased ARS securities between March 9, 2026, and June 24, 2026, and encourages affected investors to join the case by October 5, 2026. The firm operates on a contingency fee basis, ensuring no upfront costs for investors.
SPRY Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ARS Pharmaceuticals Inc.
Robbins LLP has filed a securities class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals misrepresented the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Following the announcement that CVS Caremark had delayed its decision on coverage until January 2027, ARS's stock price dropped by over 23.9% in one day.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
The Rosen Law Firm has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors who wish to serve as lead plaintiff must move the Court by October 5, 2026.
Rosen Law Firm Urges ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
The Rosen Law Firm has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals misled investors regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Shareholders who suffered losses are urged to contact the firm by October 5, 2026, to serve as lead plaintiff.
